Study to assess the efficacy, safety, and tolerability of AZD8529 in adult schizophrenia patients

Study identifier:D1960C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Active-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD8529 in Adult Schizophrenia Patients

Medical condition

schizophrenia

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match AZD8529, Placebo to match risperidone, Placebo to match risperidone

Sex

All

Actual enrollment

152

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jun 2009
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2010 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria